Phase I trial of extended-dose anti-PD-1 antibody BMS-936558 with a multipeptide vaccine for previously treated stage IV melanoma.

被引：0
|
作者：
Kudchadkar, Ragini Reiney [1 ]
Gallenstein, Donna [1 ]
Martinez, Alberto J. [1 ]
Yu, Bin [1 ]
Weber, Jeffrey S. [1 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8582
引用
收藏
页数：1
相关论文
共 50 条
  • [31] An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL)
    Sosman, Jeffrey Alan
    Martin-Algarra, Salvador
    Wolchok, Jedd D.
    Sharfman, William Howard
    Bhatia, Shailender
    Hodi, F. Stephen
    Hwu, Wen-Jen
    Gajewski, Thomas
    Slingluff, Craig L.
    Kaufman, Howard
    Gupta, Manish
    McGirr, Analia
    Horak, Christine E.
    Ahlers, Christoph Matthias
    Wigginton, Jon M.
    Urba, Walter John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC) previously treated with antiangiogenic therapy.
    Motzer, Robert John
    Bono, Petri
    Hudes, Gary R.
    Tomita, Yoshihiko
    Ravaud, Alain
    Waxman, Ian
    Gore, Martin Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Amin, Asirn
    Ernstoff, Marc S.
    Infante, Jeffrey R.
    Heng, Daniel Yick Chin
    Rini, Brian I.
    Plimack, Elizabeth R.
    McDermott, David F.
    Kollmannsberger, Christian K.
    Reaume, Martin Neil
    Spratlin, Jennifer L.
    Knox, Jennifer J.
    Voss, Martin Henner
    Pal, Sumanta Kumar
    Shen, Yuri
    Dhar, Arindarn
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors
    Sanbom, Rachel E.
    Sharfman, William Howard
    Segal, Neil Howard
    Hodi, F. Stephen
    Wolchok, Jedd D.
    Urba, Walter John
    Fox, Bernard A.
    Topalian, Suzanne Louise
    Pardoll, Drew M.
    Covello, Kelly L.
    McDonald, Dan
    Kim, Su Young
    Gupta, Ashok Kumar
    Wigginton, Jon M.
    Gajewski, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).
    Borghaei, Hossein
    Lynch, Thomas James
    Rizvi, Naiyer A.
    Chow, Laura Quan Man
    Reilly, Robert
    Crino, Lucio
    Buyse, Marc E.
    Ezzeddine, Rana
    Lestini, Brian Joseph
    Brahmer, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors
    Chow, Laura Quan Man
    Gordon, Michael S.
    Logan, Theodore F.
    Antonia, Scott J.
    Bhatia, Shailender
    Thompson, John A.
    Brahmer, Julie R.
    Solberg, Gretchen
    Bittner, Rachel
    Fontana, David
    Grosso, Joseph
    Cohen, Lewis J.
    Ahlers, Christoph Matthias
    Wigginton, Jon M.
    Drake, Charles G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL).
    Hodi, F. Stephen
    Baudelet, Christine
    Chen, Allen C.
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
    Grosso, Joseph
    Horak, Christine E.
    Inzunza, David
    Cardona, Diana M.
    Simon, Jason S.
    Gupta, Ashok Kumar
    Sankar, Vindira
    Park, Jong-Soon
    Kollia, Georgia
    Taube, Janis M.
    Anders, Robert
    Jure-Kunkel, Maria
    Novotny, Jim, Jr.
    Taylor, Clive R.
    Zhang, Xiaoling
    Phillips, Therese
    Simmons, Pauline
    Cogswell, John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.
    Callahan, Margaret K.
    Bendell, Johanna C.
    Chan, Emily
    Morse, Michael
    Pillai, Rathi Narayana
    Bono, Petri
    Jaeger, Dirk
    Evans, T. R. Jeffry
    Chau, Ian
    Calvo, Emillano
    Le, Dung T.
    Ott, Patrick Alexander
    Taylor, Matthew Hiram
    Sharma, Padmanoo
    Antonia, Scott Joseph
    Sharkey, Brian
    Christensen, Olaf
    Amin, Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Safety, durable clinical benefit, and remission resulting from nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase 1 trial in patients with previously treated metastatic renal cell carcinoma (mRCC); long-term patient follow-up
    Drake, C. G.
    Mcdermott, D. F.
    Sznol, M.
    Choueiri, T. K.
    Kluger, H. M.
    Powderly, J. D.
    Smith, D. C.
    Sankar, V.
    Gutierrez, A. A.
    Wigginton, J. M.
    Gupta, A.
    Atkins, M. B.
    BJU INTERNATIONAL, 2013, 112 : 9 - 10
12345